REVB — REVELATION BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1810560 ·
Last close
$3.88
Market Cap
$2.21M
52W High
$40.60
52W Low
$3.04
ADV30
20,409
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -3,383,576 | -3,315,513 | 10,022,097 | 9,121,630 | 2,788,395 |
| Jun 2026 | 0 | — | -3,662,241 | -3,323,384 | 12,497,932 | 11,482,792 | 2,430,946 |
| Mar 2026 | 0 | — | -3,092,500 | -3,009,051 | 15,044,282 | 14,113,415 | 2,055,329 |
| Dec 2025 | 0 | — | -2,571,588 | -2,511,006 | 11,582,924 | 10,700,331 | 2,721,929 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,327,937
Investing CF
$-111,507
Financing CF
$15,748,365
CapEx
$-111,507
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-12.31
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-55,751,722
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-11,269,340
Pretax Income TTM
$-10,750,617
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,070,814 | -8,913,649 | 11,582,924 | 2,721,929 | 8,860,995 | -8,269,581 |
| Dec 2024 | 0 | -7,975,109 | -15,038,536 | 6,622,049 | 1,913,667 | 4,708,382 | -18,321,276 |
| Dec 2023 | 0 | -8,656,664 | -120,254 | 12,212,609 | 5,564,894 | 6,647,715 | -7,286,286 |
| Dec 2022 | 0 | -10,864,511 | -10,829,549 | 5,503,415 | 4,450,962 | 1,052,453 | -11,219,396 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-10,750,617
OpCashFlow TTM
—
Assets (Latest)
$12,497,932
Forward EPS
$-20.23
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BDRX | Biodexa Pharmaceuticals Plc | $2.20M | $2.14 | — |
| CVSI | CV Sciences, Inc. | $2.17M | $0.01 | — |
| DCOY | Decoy Therapeutics Inc. | $2.26M | $0.95 | — |
| RDHL | RedHill Biopharma Ltd. | $2.13M | $0.35 | — |
| PRFX | PRF Technologies Ltd. | $2.31M | $0.66 | — |
News headlines (Yahoo Finance, 1h cache)
Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives
2026-11-16 14:00 · Yahoo
REVB Makes Major Announcement
2026-11-16 13:18 · Yahoo
REVB Approaching Important Period in Great Shape
2026-11-06 11:00 · Yahoo
Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026
2026-11-05 22:29 · Yahoo
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
2026-10-16 13:00 · Yahoo
REVB Approaching a Critical Inflection Point
2026-08-07 12:14 · Yahoo
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
2026-08-06 20:15 · Yahoo
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
2026-08-03 13:00 · Yahoo
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
2026-07-10 20:05 · Yahoo
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
2026-03-30 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.